


XR9051 hydrochloride

Cat. No.:	HY-13776A
CAS No.:	180422-22-4
Molecular Formula:	C ₃₉ H ₃₉ ClN ₄ O ₅
Molecular Weight:	679.2
Target:	P-glycoprotein
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	XR9051 hydrochloride is an orally active and specific modulator of P-glycoprotein-mediated multidrug resistance (MDR) ^[1] .																
In Vitro	<p>XR9051 is able to reverse resistance to a variety of cytotoxic drugs, including doxorubicin, etoposide and vincristine, which are associated with classical MDR^[1].</p> <p>XR9051 is highly active and gave at least a 15- to 20- fold decrease in the doxorubicin IC₅₀, in the acquired resistance cell lines^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>																
In Vivo	<p>XR9051 (20-40 mg/kg, ip) shows significant modulatory activity in mice bearing MDR human ovarian (2780AD and CH1/DOXr) and SCLC (H69/LX) xenografts^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Female Balb/c mice (20-25 g)^[2].</td> </tr> <tr> <td>Dosage:</td> <td>I.V.</td> </tr> <tr> <td>Administration:</td> <td>20 mg/kg at various times (5 min to 24 h).</td> </tr> <tr> <td>Result:</td> <td>The area under the concentration time curves (AUC) from time 0-∞ for plasma was 11.9 µg·h mL⁻¹. The ratio between AUC for tissue:plasma for liver, heart and brain were 79.6, 16.9 and 0.3 respectively.</td> </tr> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>MDR 2780AD ovarian carcinoma xenografts^[2].</td> </tr> <tr> <td>Dosage:</td> <td>I.P.</td> </tr> <tr> <td>Administration:</td> <td>20, 30, 40 mg/kg daily with Epirubicin i.v. (10 mg/kg).</td> </tr> <tr> <td>Result:</td> <td>Significantly reduced growth rate of MDR 2780AD ovarian carcinoma xenografts compared with either drug alone.</td> </tr> </table>	Animal Model:	Female Balb/c mice (20-25 g) ^[2] .	Dosage:	I.V.	Administration:	20 mg/kg at various times (5 min to 24 h).	Result:	The area under the concentration time curves (AUC) from time 0-∞ for plasma was 11.9 µg·h mL ⁻¹ . The ratio between AUC for tissue:plasma for liver, heart and brain were 79.6, 16.9 and 0.3 respectively.	Animal Model:	MDR 2780AD ovarian carcinoma xenografts ^[2] .	Dosage:	I.P.	Administration:	20, 30, 40 mg/kg daily with Epirubicin i.v. (10 mg/kg).	Result:	Significantly reduced growth rate of MDR 2780AD ovarian carcinoma xenografts compared with either drug alone.
Animal Model:	Female Balb/c mice (20-25 g) ^[2] .																
Dosage:	I.V.																
Administration:	20 mg/kg at various times (5 min to 24 h).																
Result:	The area under the concentration time curves (AUC) from time 0-∞ for plasma was 11.9 µg·h mL ⁻¹ . The ratio between AUC for tissue:plasma for liver, heart and brain were 79.6, 16.9 and 0.3 respectively.																
Animal Model:	MDR 2780AD ovarian carcinoma xenografts ^[2] .																
Dosage:	I.P.																
Administration:	20, 30, 40 mg/kg daily with Epirubicin i.v. (10 mg/kg).																
Result:	Significantly reduced growth rate of MDR 2780AD ovarian carcinoma xenografts compared with either drug alone.																

REFERENCES

[1]. I L Dale , et al. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer. 1998 Oct;78(7):885-92.

[2]. P Mistry, et al. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer. 1999 Apr;79(11-12):1672-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA